Wockhardt is preparing to launch its breakthrough antibiotic Zaynich in the US and India. The company is using scientific publications to help doctors understand the drug. Dr Habil Khorakiwala said, "These publications will provide the clinical community with robust evidence of Zaynich's therapeutic potential and support its adoption as well."
With US Food and Drug Administration (USFDA) approval in hand, Wockhardt is now focused on commercialising its breakthrough antibiotic Zaynich in the world's largest pharmaceutical market. Dr Habil Khorakiwala, chairman of the company, said in a letter to shareholders that Wockhardt is preparing for the launch of Zaynich in the US and India in the coming months, backed by key scientific publications. Zaynich, approved in the US for complicated urinary tract infections, including pyelonephritis, is the first drug discovered and developed in India to secure USFDA approval. The Mumbai-based drugmaker is supporting the upcoming launch with a publication-driven strategy aimed at accelerating physician adoption.
A global Phase III trial comparing Zaynich with meropenem has been accepted for publication in the Journal of the American Medical Association (JAMA), while a Phase II study in patients with meropenem-resistant infections has already been published in Clinical Infectious Diseases. Another paper detailing compassionate use in more than 80 critically ill patients across India, the US, France and Malaysia is expected shortly. "These publications will provide the clinical community with robust evidence of Zaynich's therapeutic potential and support its adoption as a valuable treatment option, particularly for critically ill patients facing infections caused by multidrug-resistant pathogens,"
Khorakiwala said. Wockhardt has decided to market and distribute Zaynich in the US rather than pursue an out-licensing route. In the US market, securing regulatory approval is only half the task. Commercial success will depend on winning the confidence of doctors who prescribe the drug and ensuring it is accessible to patients. This includes getting the medicine listed in formularies, or official lists of prescription medicines covered by health insurance plans. The company is simultaneously pursuing a broader global footprint for the antibiotic. The European Medicines Agency has accepted the dossier for review across multiple indications, including complicated intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia and bloodstream infections, with a decision expected in the coming months.
Wockhardt has also received approval from India's Central Drugs Standard Control Organisation (CDSCO) for manufacturing and marketing the drug. Pipeline progress Beyond Zaynich, Khorakiwala highlighted progress across the company's innovation portfolio. Wockhardt recently filed a New Drug Application for Foviscu (WCK 4282), a novel antibiotic aimed at resistant Gram-negative infections. Phase III trials showed efficacy comparable to meropenem, positioning it as a potential carbapenem-sparing alternative. Another novel antibiotic, Miqnaf (nafithromycin), is expanding beyond its approved indication in community-acquired bacterial pneumonia.
A Phase III study in acute bacterial rhinosinusitis has been completed successfully, and a supplemental filing is planned in the coming quarter. The company is also advancing Odrate (WCK 6777), which is expected to enter Phase II studies for multidrug-resistant Gram-negative infections. "Our commitment to antibiotic discovery extends beyond the successful development of individual molecules," Khorakiwala said. "We continue to accelerate the clinical development of our pipeline assets to expand their therapeutic utility and address evolving patterns of antimicrobial resistance." Biotech investments The innovation push comes amid improving business performance.
Wockhardt reported a 24% rise in second-quarter revenue to Rs 969 crore, while EBITDA stood at Rs 165 crore. Excluding pre-launch expenses related to Zaynich, EBITDA would have been Rs 201 crore. First-half revenue grew 25% to Rs 1,898 crore, with EBITDA rising 35% to Rs 353 crore. The company's biotech business also emerged as a key growth driver. Biotech revenue surged 68% year-on-year to Rs 252 crore in the quarter and 87% in the first half to Rs 487 crore, driven by strong demand for insulin products in India and emerging markets. Wockhardt said it is investing in expanding manufacturing capabilities for its diabetes biosimilars portfolio, including human insulin and insulin glargine, to support growth and entry into new geographies.
"As we continue to accelerate the development of breakthrough antibiotics, our aspiration remains clear: to deliver differentiated treatment options for patients worldwide while reinforcing India's position as a credible source of globally relevant pharmaceutical innovation," Khorakiwala said.
